vs
HCA Healthcare（HCA）与礼来（LLY）财务数据对比。点击上方公司名可切换其他公司
礼来的季度营收约是HCA Healthcare的1.0倍（$19.3B vs $19.1B），礼来净利率更高（34.4% vs 9.7%，领先24.7%），礼来同比增速更快（42.6% vs 4.3%），过去两年礼来的营收复合增速更高（48.3% vs 4.5%）
HCA Healthcare是1968年成立的美国营利性医疗服务运营商，总部位于田纳西州纳什维尔。截至2020年5月，其在全美20个州及英国运营186家医院，以及手术中心、独立急诊室、急症护理中心、医师诊所等约2400个各类医疗站点，业务覆盖范围广泛。
礼来（Eli Lilly and Company）是总部位于美国印第安纳州印第安纳波利斯的跨国制药企业，1876年由美国内战时期联邦军退伍药剂师伊莱·礼来创立，目前在18个国家设有办事处，产品销往全球约125个国家，是全球知名的制药厂商。
HCA vs LLY — 直观对比
营收规模更大
LLY
是对方的1.0倍
$19.1B
营收增速更快
LLY
高出38.3%
4.3%
净利率更高
LLY
高出24.7%
9.7%
两年增速更快
LLY
近两年复合增速
4.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $19.1B | $19.3B |
| 净利润 | $1.9B | $6.6B |
| 毛利率 | — | 82.5% |
| 营业利润率 | — | 42.8% |
| 净利率 | 9.7% | 34.4% |
| 营收同比 | 4.3% | 42.6% |
| 净利润同比 | 1.8% | 50.5% |
| 每股收益（稀释后） | $7.15 | $7.39 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HCALLY
| Q1 26 | $19.1B | — | ||
| Q4 25 | $19.5B | $19.3B | ||
| Q3 25 | $19.2B | $17.6B | ||
| Q2 25 | $18.6B | $15.6B | ||
| Q1 25 | $18.3B | $12.7B | ||
| Q4 24 | $18.3B | $13.5B | ||
| Q3 24 | $17.5B | $11.4B | ||
| Q2 24 | $17.5B | $11.3B |
净利润HCALLY
| Q1 26 | $1.9B | — | ||
| Q4 25 | $1.9B | $6.6B | ||
| Q3 25 | $1.6B | $5.6B | ||
| Q2 25 | $1.7B | $5.7B | ||
| Q1 25 | $1.6B | $2.8B | ||
| Q4 24 | $1.4B | $4.4B | ||
| Q3 24 | $1.3B | $970.3M | ||
| Q2 24 | $1.5B | $3.0B |
毛利率HCALLY
| Q1 26 | — | — | ||
| Q4 25 | — | 82.5% | ||
| Q3 25 | — | 82.9% | ||
| Q2 25 | — | 84.3% | ||
| Q1 25 | — | 82.5% | ||
| Q4 24 | — | 82.2% | ||
| Q3 24 | — | 81.0% | ||
| Q2 24 | — | 80.8% |
营业利润率HCALLY
| Q1 26 | — | — | ||
| Q4 25 | 13.7% | 42.8% | ||
| Q3 25 | 12.6% | 41.1% | ||
| Q2 25 | 13.0% | 43.6% | ||
| Q1 25 | 12.7% | 27.2% | ||
| Q4 24 | 11.7% | 37.2% | ||
| Q3 24 | 10.9% | 13.9% | ||
| Q2 24 | 12.8% | 31.1% |
净利率HCALLY
| Q1 26 | 9.7% | — | ||
| Q4 25 | 9.6% | 34.4% | ||
| Q3 25 | 8.6% | 31.7% | ||
| Q2 25 | 8.9% | 36.4% | ||
| Q1 25 | 8.8% | 21.7% | ||
| Q4 24 | 7.9% | 32.6% | ||
| Q3 24 | 7.3% | 8.5% | ||
| Q2 24 | 8.4% | 26.3% |
每股收益（稀释后）HCALLY
| Q1 26 | $7.15 | — | ||
| Q4 25 | $8.09 | $7.39 | ||
| Q3 25 | $6.96 | $6.21 | ||
| Q2 25 | $6.83 | $6.29 | ||
| Q1 25 | $6.45 | $3.06 | ||
| Q4 24 | $5.66 | $4.88 | ||
| Q3 24 | $4.88 | $1.07 | ||
| Q2 24 | $5.53 | $3.28 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $940.0M | $7.3B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $26.5B |
| 总资产 | $19.3B | $112.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资HCALLY
| Q1 26 | $940.0M | — | ||
| Q4 25 | $1.0B | $7.3B | ||
| Q3 25 | $997.0M | $9.9B | ||
| Q2 25 | $939.0M | $3.5B | ||
| Q1 25 | $1.1B | $3.2B | ||
| Q4 24 | $1.9B | $3.4B | ||
| Q3 24 | $2.9B | $3.5B | ||
| Q2 24 | $831.0M | $3.4B |
总债务HCALLY
| Q1 26 | — | — | ||
| Q4 25 | $44.3B | — | ||
| Q3 25 | $42.6B | — | ||
| Q2 25 | $42.7B | — | ||
| Q1 25 | $44.6B | — | ||
| Q4 24 | $43.0B | $29.5B | ||
| Q3 24 | $43.0B | — | ||
| Q2 24 | $40.9B | — |
股东权益HCALLY
| Q1 26 | — | — | ||
| Q4 25 | $-6.0B | $26.5B | ||
| Q3 25 | $-5.3B | $23.8B | ||
| Q2 25 | $-4.4B | $18.3B | ||
| Q1 25 | $-3.5B | $15.8B | ||
| Q4 24 | $-2.5B | $14.2B | ||
| Q3 24 | $-2.2B | $14.2B | ||
| Q2 24 | $-1.6B | $13.6B |
总资产HCALLY
| Q1 26 | $19.3B | — | ||
| Q4 25 | $60.7B | $112.5B | ||
| Q3 25 | $59.7B | $114.9B | ||
| Q2 25 | $59.5B | $100.9B | ||
| Q1 25 | $59.8B | $89.4B | ||
| Q4 24 | $59.5B | $78.7B | ||
| Q3 24 | $59.5B | $75.6B | ||
| Q2 24 | $57.4B | $71.9B |
负债/权益比HCALLY
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 2.08× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.0B | $3.2B |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | 1.08× | 0.49× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流HCALLY
| Q1 26 | $2.0B | — | ||
| Q4 25 | $2.4B | $3.2B | ||
| Q3 25 | $4.4B | $8.8B | ||
| Q2 25 | $4.2B | $3.1B | ||
| Q1 25 | $1.7B | $1.7B | ||
| Q4 24 | $2.6B | $2.5B | ||
| Q3 24 | $3.5B | $3.7B | ||
| Q2 24 | $2.0B | $1.5B |
自由现金流HCALLY
| Q1 26 | — | — | ||
| Q4 25 | $870.0M | — | ||
| Q3 25 | $3.1B | — | ||
| Q2 25 | $3.0B | — | ||
| Q1 25 | $660.0M | — | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $2.3B | — | ||
| Q2 24 | $690.0M | — |
自由现金流率HCALLY
| Q1 26 | — | — | ||
| Q4 25 | 4.5% | — | ||
| Q3 25 | 16.3% | — | ||
| Q2 25 | 16.3% | — | ||
| Q1 25 | 3.6% | — | ||
| Q4 24 | 7.0% | — | ||
| Q3 24 | 13.3% | — | ||
| Q2 24 | 3.9% | — |
资本支出强度HCALLY
| Q1 26 | — | — | ||
| Q4 25 | 7.6% | — | ||
| Q3 25 | 6.7% | — | ||
| Q2 25 | 6.3% | — | ||
| Q1 25 | 5.4% | — | ||
| Q4 24 | 7.0% | — | ||
| Q3 24 | 6.8% | — | ||
| Q2 24 | 7.3% | — |
现金转化率HCALLY
| Q1 26 | 1.08× | — | ||
| Q4 25 | 1.26× | 0.49× | ||
| Q3 25 | 2.69× | 1.58× | ||
| Q2 25 | 2.55× | 0.55× | ||
| Q1 25 | 1.03× | 0.60× | ||
| Q4 24 | 1.78× | 0.56× | ||
| Q3 24 | 2.77× | 3.83× | ||
| Q2 24 | 1.35× | 0.49× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HCA
暂无分部数据
LLY
| Other | $5.4B | 28% |
| Zepbound | $4.2B | 22% |
| Mounjaro | $4.1B | 21% |
| Verzenio | $997.1M | 5% |
| Collaborationand Other Revenue | $991.7M | 5% |
| Taltz | $724.3M | 4% |
| Trulicity | $692.8M | 4% |
| Other Cardiometabolic Health | $524.5M | 3% |
| Other Oncology | $514.8M | 3% |
| Jardiance | $465.8M | 2% |
| Neuroscience | $320.2M | 2% |
| Other Immunology | $187.3M | 1% |
| Other Product Total | $77.0M | 0% |
